下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認領(lǐng)
文檔簡介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEDeguelinCat. No.: HY-13425CAS No.: 522-17-8Synonyms: (-)-Deguelin; (-)-cis-Deguelin分式: CHO分量: 394.42作靶點: Akt作通路: PI3K/Akt/mTOR儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 50 mg/mL (126.7
2、7 mM; Need ultrasonic)H2O : 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (6.34 mM); Clear solution2. 請依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (6.34 mM); Suspended solution; Need ultrasonic1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE3. 請依序添加每種溶劑: 10% DMSO 90%
3、 corn oilSolubility: 2.5 mg/mL (6.34 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Deguelin種天然存在的類胡蘿素, 種有效的 PI3K/AKT 抑制劑。IC50 & Target Akt體外研究 Deguelin (0-500 nM) in a dose and time dependent manner inhibits the growth of MDA-MB-231, MDA-MB-468, BT-549 and BT-20 cells. Deguelin at all concentrations fai
4、ls to reduce cell numbers in the presence of 1ng EGF but in the presence of EGF 20 ng reinstated deguelin mediated growth inhibition. Deguelin treatedcells show reduced expression of Survivin as determined by western blot and immunofluorescenceexaminations. Deguelin inhibits p-ERK and its downstream
5、 target p-STAT-3 and c-Myc expression in a dosedependent manner 1. Deguelin down-regulates Akt signaling probably by disrupting its association with Hsp90 in cultured HNSCC cells. Deguelin deguelin disrupts the association between Hsp 90 with survivin andCdk4. Deguelin deguelin treatment increases c
6、ellular ceramide level through de novo synthase pathway tomediate HNSCC cell death and apoptosis 2. Deguelin inhibits the proliferation of MPC-11 cells in aconcentration- and time-dependent manner and causes the apoptotic death of MPC-11 cells. Followingexposure to deguelin, the phosphorylation of A
7、kt is decreased. Deguelin-induced apoptosis is characterizedby the upregulation of Bax, downregulation of Bcl-2 and activation of caspase-3 3.體內(nèi)研究 Deguelin (2 or 4 mg/kg, i.p.) reduces the in vivo tumor growth of MDA-MB-231 cells transplantedsubcutaneously in athymic mice 1. Deguelin (4 mg/kg, p.o.)
8、 treatment shows a great inhibition in tumorgrowth, which is demonstrated by reduced tumor size and improved mice survival and, indicating a significantanti-tumor ability by deguelin in vivo 2. In the colon cancer xenograft model, the volume of the tumor treatedwith deguelin is significantly lower t
9、han that of the control, and the apoptotic index for deguelin-treated miceis much higher 4.PROTOCOLKinase Assay 2 Caspase 3 activity is determined using Caspase-Glo-3 assays. This assay provides luminogenic substrate ina buffer system optimized for each specific caspase activity. The caspase cleavag
10、e of the substrate isfollowed by generation of a luminescent signal. The signal generated is proportional to the amount ofcaspase activity present in the sample. Protein (10 g) from the cell samples is diluted in water to a finalvolume of 50 L and added to a white 96-well microtitre plate, followed
11、by 50 L of Caspase-Glo-3 reagent.The plate is sealed and gently mixed at 300-500 rpm for 30 s and incubated at room temperature for 30 min.Luminescence is measured in a microplate reader (TECAN Infinite 200).MCE has not independently confirmed the accuracy of these methods. They are for reference on
12、ly.Cell Assay 1 Breast cancer cells are incubated with increasing concentration of Deguelin ranging from 31 nM to 500 nMfor 24, 48 and 72 h. At the termination the cells are trypsinized and cell proliferation is evaluated by counting2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEcells using Z-seri
13、es Coulter counter. Data are presented as MeanSE percent of control.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Six to seven weeks old female athymic mice (nu/nu) are housed in a barrier free environment under 242CAdministration 1 temperature
14、, 5010% relative humidity, and 12-hour light/12-hour dark cycle. Mice are provided with sterilemouse chow and water ad libitum. MDA-MB-231 cells (3.0 million cells/animal) are suspended in sterile PBSand then injected subcutaneously into the dorsal flank region using 23 g hypodermic needle. Animals
15、areobserved daily for the growth of palpable tumor at the site of injection. Once the tumor (approximately 50mm3) appears, the mice are randomized in to three groups, animals receiving either 1) vehicle as a control 2)Deguelin treatment at 2 mg/kg bodyweight dose or 3) Deguelin at 4 mg/kg body weigh
16、t. Each group consistsof 10 animals. Vehicle or Deguelin is administered through i.p. injection daily for 21 days. Animals aremonitored daily for the signs of drug/vehicle associated toxicity and weighed once weekly. Growth of tumor atthe site of cell injection is monitored every alternate day and o
17、f tumor size is measured using calipers. Tumorvolume is calculated by using the well-established formula: tumor volume (mm3)=/6 lengthwidthdepth.Data represent the mean tumor volume+SE (mm3) in each group. The animals are sacrificed at the indicatedtime unless they appear to be moribund or tumors sh
18、ow sign of necrosis. At termination, the tumor isexcised, freed from connective tissue and other organs, a small piece is fixed in 10% buffered formalin andremaining tumor is snap frozen for future biochemical analysis. Liver, lung, kidney and spleen are excisedand weighed.MCE has not independently
19、confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻 Int J Mol Med. 2018 Jun;41(6):3157-3166.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Mehta R, et al. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells. PLoS One. 2013 Jun10;8(6):e65113.2. Yang YL, et al. Deguelin induces both apoptosis and auto
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
- 6. 下載文件中如有侵權(quán)或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2024-2030年中國電子鎖市場發(fā)展商機及需求趨勢預(yù)測研究報告
- 2024-2030年中國電動產(chǎn)床行業(yè)發(fā)展分析及發(fā)展前景與趨勢預(yù)測研究報告
- 2024-2030年中國甲基環(huán)己烷行業(yè)銷售渠道及前景供需狀況分析研究報告
- 2024-2030年中國生物質(zhì)能開發(fā)利用行業(yè)發(fā)展?jié)摿εc投資前景預(yù)測報告
- 2024-2030年中國生物基聚對苯二甲酸乙二醇酯行業(yè)市場發(fā)展趨勢與前景展望戰(zhàn)略研究報告
- 2024-2030年中國瑪莎玉米產(chǎn)品市場營銷模式與發(fā)展趨勢研究研究報告
- 2024-2030年中國豬圓環(huán)疫苗市場應(yīng)用進展趨勢與發(fā)展方向戰(zhàn)略研究研究報告
- 2024-2030年中國燃氣汽車行業(yè)市場發(fā)展分析及投資前景與策略研究報告
- 教育培訓平臺課程設(shè)計與推廣合同
- 2024-2030年中國燒烤調(diào)料行業(yè)消費需求及競爭態(tài)勢研究報告
- 講師授課評分表
- 鐵道概論全套課件
- 三年級數(shù)學上冊課件-5. 倍的認識 - 人教版(共16張PPT)
- 支撐架施工驗收記錄表
- 2022版義務(wù)教育語文課程標準解讀之核心素養(yǎng)與課程目標PPT
- 2021秋季教科版五年級科學上冊教案((全冊))
- 學習習慣思維導圖模板
- 立體構(gòu)成基本形態(tài)要素-點
- 國外低碳經(jīng)濟的發(fā)展概況
- 故鄉(xiāng)教學設(shè)計一等獎
- GB-T 13861-2022 生產(chǎn)過程危險和有害因素分類與代碼(高清版)
評論
0/150
提交評論